ExoCoBio Completes Acquisition of BENEV, a Global Medical Aesthetic Brand

">With the acquisition of BENEV, ExoCoBio solidifies its position as a global leader in exosome-based regenerative aesthetics. This strategic partnership allows ExoCoBio to further expand the commercialization of exosome technology on a global scale.

BENEV, a renowned medical aesthetic brand established in 2000, has been at the forefront of the industry. Their groundbreaking growth factor-based skincare products have set them apart from competitors. In addition to their skincare line, they have also introduced innovative products like an award-winning RF microneedling system, top-of-the-line PDO threads, and the Exosome Regenerative Complex developed by ExoCoBio.

BENEV's success can be attributed to their expertise in what they call their "Regenerative Trifecta" - three categories that encompass their core offerings. With an impressive compound annual growth rate (CAGR) of over 117% in total revenue over the past three fiscal years, BENEV has established itself as a dominant player in the U.S. aesthetic medical market.

Under this new partnership, ExoCoBio will